author-photo

Lone Ottesen

AstraZeneca

9

Papers

176

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (112)
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.

2020 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
A Comprehensive Methodology to Systematically Identify Drug Hypersensitivity and Anaphylactic Reactions in Clinical Trial Databases.

2020 Pharmaceutical medicine
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.

2020 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (35)
Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

2019 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (13)
VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)